Appendix 4D and Financial Report for half-year to 30 June 19
Filed with ASX · · 27 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call*** Subsequent to the end of the half-year,** on 24 July 2019, 30,700,000 fully paid ordinary shares were issued further to a private placement announced on 17 July 2019. Shares were issued at $1.30 per share to raise $40,001,000 before costs. On 22 August 2019, 3,846,128 fully paid ordinary shares were issued further to the Share Purchase Plan (SPP) announced on 17 July 2019 to raise a total amou
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- First Australian Patient Dosed in ZIRCON Phase III Trial
- Telix Pharmaceuticals announces results of successful SPP
- Telix and GenesisCare Commence Prostate Cancer Study
- Telix and Merck Group Combination Therapy Collaboration
- Sales Note to Accompany June 2019 Quarter Appendix 4C
Later from Telix Pharmaceuticals
- FDA Pre-NDA Meeting Outcomes - TLX591-CDx illumet
- Telix to Acquire European Production Facility
- Appendix 4C - September 2019 quarter
- Telix and AusHealth Partner for Lung, Ovarian Cancer
- Telix and ATONCO Partner for Bladder Cancer
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals